Contact Information:

Media Contact

Edyta Zielinska

Twitter: JeffersonUniv

Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości. - Press Release Distribution
RSS - Press News Release
Add Press Release

Practice-changing study offers new option for tough breast cancer cases

PALOMA-3 results show that the newly approved drug palbociclib could offer an effective and less toxic option for therapy

( (PHILADELPHIA) -- Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer. The results will be presented at the 2015 annual American Society of Clinical Oncology (ASCO, abstract LBA-502) and published in the New England Journal of Medicine. "These are women with advanced metastatic cancer whose disease was kept in check without the use of toxic and life-disrupting chemotherapy," says Dr. Massimo Cristofanilli, M.D., Director of the Breast Care Center at Thomas Jefferson University and senior author of the study. "This is a major advance for this population of women for which we had very few active options and are often treated with chemotherapy alone."

The study, called the PALOMA-3, enrolled 521 pre-/peri- and postmenopausal patients with hormone receptor positive and human epidermal growth factor receptor-negative (HR+/HER2-) advanced disease. These women had typically already relapsed on hormone therapy and were not candidates for the HER2-blocking therapy herceptin. The patients were randomized to treatment and control arms at a 2:1 ratio (with 345 treated and 172 receiving placebo). The treatment arm received palbociclib together with standard of care for this population, fulvestrant, a drug that blocks the hormone receptor via a different mechanism than first-line therapies. The placebo arm received fulvestrant plus placebo.

The study experienced very rapid enrollment and at the preplanned independent data and safety monitoring review panel, the study was stopped early only 10 months after the study commenced because it met the primary endpoint of improving progression-free survival (time to cancer relapse). Patients taking palbociclib plus fulvestrant showed a median progression-free survival of 9.2 months compared to 3.8 months on fulvestrant plus placebo. Progression or recurrence of cancer occurred in only 25 percent of palbociclib plus fulvestrant treated patients versus 50 percent of patients treated with fulvestrant alone.

Palbociclib was approved by the Food and Drug Administration (FDA) on February 3rd, 2015, based on data from the PALOMA-1, an earlier phase 2 clinical trial in postmenopausal women with newly-diagnosed estrogen receptor (ER+)/HER2- breast cancer that had not received any treatment for their advanced disease. PALOMA-1 showed that palbociclib in combination with the estrogen-production blocker, letrozole, doubled the time it took for metastatic cancer to recur from a median of 10 months with letrozole plus placebo, to 20 months for palbociclib plus letrozole. The drug was approved by the FDA as a combination first-line therapy for postmenopausal women with ER+/HER2- breast cancer, as initial endocrine-based treatment for their metastatic disease.

The current PALOMA-3 study demonstrates benefit in a population of women with a later stage of metastatic breast cancer. For example, women whose cancer was no longer controlled by letrozole or other aromatase inhibitors, those who had already begun to receive chemotherapy, and premenopausal patients with metastatic disease.

"Part of what was exciting about the design of this clinical trial is that we decided early on to accept women from a younger and generally sicker population than is typically enrolled in clinical trials," says Dr. Cristofanilli, who is also a researcher at the Sidney Kimmel Cancer Center at Thomas Jefferson University. "The PALOMA-3 study showed that palbociclib extends the time to progression of disease while maintaining very good quality of life."

The most commonly reported side effects were a decrease in certain populations of immune cells, conditions called neutropenia and leukopenia, an expected effect that indicates the drug is working. The rates of nausea and fatigue were low and overall slightly elevated over placebo group, but the increase was not statistically significant. The drug was better tolerated than other biological therapies used in this setting. Furthermore, there was a significant difference in quality of life as measured by the rate of clinical deterioration of symptomatic disease in patients treated with the investigational combination.

Typically the first-line therapy for ER+ positive patients is to administer hormone therapy, which blocks cellular growth and reproduction signals that are triggered by the hormone estrogen and the estrogen receptor. However, many ER+ breast cancers begin to take advantage of alternative growth pathways. Palbociclib blocks a major alternate route, called the CDK4/6 growth signal, by inhibiting cancer cell proliferation and cellular division.

"Although palbociclib has yet to be approved for this population of women, this study is likely to be practice changing," says Dr. Cristofanilli, a practicing oncologist. "I don't envision a situation where single-agent endocrine therapy would be appropriate any longer for ER+/Her2- metastatic breast cancer patients."

"Pfizer extends our deepest thanks to the investigators of the PALOMA-3 study for their efforts in leading a successful trial, and most importantly, the more than 500 women for their participation," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology. "Patients with HR+, HER2- metastatic breast cancer whose disease have progressed after endocrine therapy have significant unmet needs, and we're pleased with the results of this study that demonstrate the potential for palbociclib as an important treatment option for this patient population."


The study was sponsored by Pfizer. Dr. Cristofanilli did not receive any honoraria or individual research support from Pfizer. The authors have no other conflicts to report.

For more information, contact Edyta Zielinska. Office: 215-955-5291, cell: 215-847-5884,

About Jefferson -- Health is all we do.

Our newly formed organization, Jefferson, encompasses Jefferson Health and Thomas Jefferson University, representing our clinical and academic entities. Together, the people of Jefferson, 19,000 strong, provide the highest-quality, compassionate clinical care for patients, educate the health professionals of tomorrow, and discover new treatments and therapies that will define the future of health care.

Jefferson Health comprises five hospitals, 13 outpatient and urgent care centers, as well as physician practices and everywhere we deliver care throughout the city and suburbs across Philadelphia, Montgomery and Bucks Counties in Pa., and Camden County in New Jersey. Together, these facilities serve more than 78,000 inpatients, 238,000 emergency patients and 1.7 million outpatient visits annually. Thomas Jefferson University Hospital is the largest freestanding academic medical center in Philadelphia. Abington Hospital is the largest community teaching hospital in Montgomery or Bucks counties. Other hospitals include Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; and Abington-Lansdale Hospital in Hatfield Township.

Thomas Jefferson University enrolls more than 3,900 future physicians, scientists, nurses and healthcare professionals in the Sidney Kimmel Medical College (SKMC); Jefferson Schools of Health Professions, Nursing, Pharmacy, Population Health; and the Graduate School of Biomedical Sciences, and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center

For more information and a complete listing of Jefferson services and locations, visit


Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study. "This study provides a new option for postmenopausal women undergoing treatment ...

Duke's poliovirus study finds that less is more

DURHAM, N.C. - A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered. The dosage findings for the first 20 patients in the phase 1 trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago at the end of the month (abstract #2068). "The purpose of a phase 1 trial is to identify the optimal dose to minimize toxicity," said ...

50 shades of endangered: Marsupial mating habits to die for

Queensland scientists have discovered two more species of suicidally-sexed marsupials and one is already destined for the threatened list. Queensland University of Technology's (QUT) Dr Andrew Baker and his team have named two new species of Dusky Antechinus. One new species was discovered in remote, south-eastern Tasmania and another mainland form was raised to species status. The team has now discovered five new species of antechinus in the past three years, a 50 per cent increase in diversity within this long-known genus of mammals. However, the researchers believe ...

Mount Sinai researchers to present key cancer trial data at ASCO

(New York - May 26, 2015) Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology (ASCO) annual meeting, May 29 - June 2, 2015, in Chicago. ASCO is the world's largest oncology meeting, with more than 25,000 researchers presenting their latest study results. Key abstract presentations include: * In situ vaccine for low-grade lymphoma: Combination of intratumoral ...

Novel X-ray lens sharpens view into the nano world

Novel X-ray lens sharpens view into the nano world
This news release is available in German. A team led by DESY scientists has designed, fabricated and successfully tested a novel X-ray lens that produces sharper and brighter images of the nano world. The lens employs an innovative concept to redirect X-rays over a wide range of angles, making a high convergence power. The larger the convergence the smaller the details a microscope can resolve, but as is well known it is difficult to bend X-rays by large enough angles. By fabricating a nano-structure that acts like an artificial crystal it was possible to mimic ...

Finnish-Swedish study analyzes link between psychotropic drugs and homicide risk

A study analysing the Finnish homicide and prescription drug databases discovered that the use of certain drugs that affect the central nervous system are associated with an increased risk of committing a homicide. The greatest risk was associated with the use of painkillers and tranquillizing benzodiazepines, while anti-depressants were linked only to a slightly elevated risk. The study is the first one of its kind in the world. Professor Jari Tiihonen's research group analysed the use of prescription drugs of 959 persons convicted of a homicide. In the recent years, ...

People more likely to cheat as they become more economically dependent on their spouses

WASHINGTON, DC, May 27, 2015 -- Both men and women are more likely to cheat on their spouses the more economically dependent they are on them, according to a new study. "You would think that people would not want to 'bite the hand that feeds them' so to speak, but that is not what my research shows," said study author Christin L. Munsch, an assistant professor of sociology at the University of Connecticut. "Instead, the findings indicate people like feeling relatively equal in their relationships. People don't like to feel dependent on another person." According to ...

Western diet may increase risk of death after prostate cancer diagnosis

Boston, MA -- After a prostate cancer diagnosis, eating a diet higher in red and processed meat, high-fat dairy foods, and refined grains--known as a Western diet--may lead to a significantly higher risk of both prostate cancer-related mortality and overall mortality compared with eating a diet rich in vegetables, fruits, fish, whole grains, and healthy oils, according to a new study from Harvard T.H. Chan School of Public Health. The study, which appears online June 1, 2015 in the journal Cancer Prevention Research, offers insight on how diet may help improve survivorship ...

Patient information too high for patients' literacy: New research

More than 90 per cent of educational materials written for kidney disease patients is higher than an average patient's literacy, according to a new study published in the June issue of the National Kidney Foundation's American Journal of Kidney Diseases. "Our study suggests most patient information materials are not fit for their intended purpose, and that organisations are producing materials that may be too difficult for their intended audience to understand," said Angela Webster, lead researcher and an Associate Professor Clinical Epidemiology at the University of ...

Massive weight loss fuels surge in plastic surgery

Massive weight loss fuels surge in plastic surgery
ARLINGTON HEIGHTS, Ill., June 1, 2015 - An increase in the number of weight loss surgeries in the U.S. is beginning to have a ripple effect in plastic surgery, according to new data released today by the American Society of Plastic Surgeons (ASPS). Procedures specifically associated with massive weight loss, including tummy tucks, thigh lifts, breast lifts and upper arm lifts, grew at their fastest rate in four years in 2014, according to the report. That follows a similar increase in the growth of weight loss surgeries. "We think there is a correlation between the two ...


How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[] Practice-changing study offers new option for tough breast cancer cases
PALOMA-3 results show that the newly approved drug palbociclib could offer an effective and less toxic option for therapy is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.